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Abstract
Background: Excessive neutrophil presence and activation is important in a number of acute and chronic
inflammatory diseases. The CXCR2 chemokine receptor is important in controlling the extravasation and activation
of neutrophils. Selective antagonism of the CXCR2 receptor is a potential approach to reducing neutrophil migration
and activation. Danirixin, is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory
medicine.
Methods: (1) First time in human (FTIH) double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics,
and pharmacodynamics of single ascending and repeat oral doses of danirixin in healthy male subjects; (2) single-dose
study of age, gender, food, and proton-pump inhibitor effects on the pharmacokinetics of danirixin in healthy
adult subjects; and placebo-controlled study of the pharmacokinetics of danirixin in healthy elderly subjects.
Results: There were no serious adverse events and no adverse events considered to be of clinical relevance. There
were no withdrawals due to adverse events. Systemic exposure following single doses of danirixin 10 mg, 25 mg,
50 mg, 100 mg, and 200 mg increased with increasing dose. Engagement of pharmacology was demonstrated as
inhibition of ex-vivo CXCL1-induced CD11b expression on peripheral blood neutrophils when compared to placebo
(approximately 50 % for 50 mg and 100 mg danirixin, and 72 % at 200 mg). There was a 37 % decrease in Cmax and a
16 % decrease in AUC (0-∞) following administration of danirixin in the presence of food. Cmax also decreased by 65 %
when danirixin 100 mg was administered following omeprazole 40 mg once daily for 5 days. The AUC (0-∞) and Cmax
were 50 % lower in elderly subjects compared with younger subjects.
Conclusion: The dose-dependent inhibition of agonist-induced neutrophil activation following single and
repeated once daily oral administration of danirixin suggests that this CXCR2 antagonist may have benefit in
neutrophil-predominant inflammatory diseases. Co-administration with food, gastric acid reducing agents, and
variable exposure in the elderly have important clinical implications that need to be taken into consideration in
subsequent clinical evaluations.
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Background
Chemokines acting through specific receptors are able
to recruit leukocytes to sites of inflammation, resulting
in the subsequent release of a number of mediators,
including neutrophil elastase and matrix metalloprotein-
ases, which likely play an important role in disease
pathophysiology [1]. For several acute and chronic
pulmonary diseases, chemokines are thought to be im-
portant mediators driving the tissue destruction and air-
way and parenchymal remodeling associated with
disease progression [2, 3].
Selective antagonism of the interaction between the
CXCR2 chemokine receptor and its various ligands
provides a potential targeted strategy for reducing the
underlying inflammation that contributes to the deleteri-
ous effects of an excessive neutrophil response [2]. In
particular, a CXCR2 antagonist may be useful in the
treatment of respiratory diseases such as chronic ob-
structive pulmonary disease (COPD) that are associated
with a high tissue burden of activated neutrophils. The
potential for CXCR2 antagonism to reduce neutrophil
recruitment into the lung has been demonstrated previ-
ously in experimental human models of lung inflamma-
tion (ozone challenge) [4, 5] and in initial studies in
patients with severe asthma and COPD [6–8]. Transient
reductions in blood neutrophils have been observed with
two recent small molecule CXCR2 antagonists following
short and long term oral administration leading to con-
cerns about a potential impact on host defense and innate
immunity, particularly with chronic use. It is therefore
desirable to identify a CXCR2 antagonist that would
have the intended efficacy in the target tissues without
substantially impacting circulating neutrophil counts.
Danirixin is a small molecule, non-peptide, high affinity
(IC50 for CXCL8 binding = 12.5 nM), selective, and revers-
ible CXCR2 antagonist. This compound has demonstrated
potent antagonism of CXCR2 activity in vitro and anti-
inflammatory effects in various preclinical models. Its
pharmacologic activity and duration of action following
oral administration support its potential use as an oral,
anti-inflammatory agent.
The results of two clinical pharmacology studies with
danirixin are described in this report. The first time in hu-
man (FTIH) study was conducted to investigate the safety,
tolerability, pharmacokinetics, and pharmacodynamics of
single and repeat oral doses of danirixin in healthy adult
male subjects. The second study explored the effects of age,
gender, food (high fat meal), and a proton-pump inhibitor
(omeprazole) on the pharmacokinetics of danirixin.
Methods
Danirixin formulation
The structure of danirixin free base is shown in Fig. 1.
Immediate release (IR) tablets contained danirixin free
base and standard excipients including mannitol, micro-
crystalline cellulose, HPMC, croscarmellose sodium and
magnesium stearate.
Study designs and study subjects
Clinical studies were conducted in accordance with the
Declaration of Helskini. Prior to study initiation ap-
provals from appropriate regulatory authorities and eth-
ics committee/institutional review boards were obtained.
Written, informed consent was obtained from participat-
ing subjects prior to the performance of any study re-
lated assessments and procedures.
Study 1, FTIH (GSK Protocol CX3112483, ClinicalTrials.-
gov identifier NCT01209052, reviewed and approved by
the Brent Medical Ethics Committee, Harrow, UK)
The first time in human study was a single-center, ran-
domized, double-blind, placebo-controlled, adaptive design
comprising five cohorts. Two cohorts of 15 healthy non-
smoking male subjects aged 18 to 65 years were random-
ized to receive single escalating oral doses of danirixin.
Cohort 1 received doses of 10 mg, 50 mg and 200 mg; Co-
hort 2 received doses of 25 mg, 100 mg (as a single tablet)
and 100 mg (as 2 × 50 mg tablets), as well as placebo. An
interlocking design allowed a period of at least 7 days to
elapse between dosing in one cohort and administration of
a higher dose in the other cohort. Subjects in Cohorts 3
and 4 received repeat doses of danirixin or placebo once
daily for 14 days in a parallel-group design. Fourteen sub-
jects in each cohort were randomized 5:2 to receive danir-
ixin 50 mg (Cohort 3) or 200 mg (Cohort 4) or placebo.
Cohort 5 consisted of 15 subjects. Ten subjects were ran-
domized to receive danirixin 400 mg and five subjects re-
ceived placebo as a single dose. The schematic for the
study design of the FTIH study is depicted in Fig. 2.
Fig. 1 Danirixin Free Base
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Study 2, Fed versus Fasted, with Omeprazole (GSK
Protocol CX3113722, ClinicalTrials.gov identifier NCT
01209104, reviewed and approved by the Western Insti-
tutional Review Board, Olympia, WA, USA)
Study 2 was conducted at a single center in two paral-
lel parts as depicted in Fig. 3. Cohort 1 was a partially
randomized, open-label, single-dose, crossover study in
16 healthy male and female adult subjects between 40
and 64 years of age. In treatment periods 1 and 2,
subjects were randomized to two single dose treatment
regimens in a crossover fashion, in the fed (after a high-
fat meal) and fasted states. In treatment period 3, sub-
jects were administered omeprazole once daily for 5 days.
On the fifth day, all subjects received danirixin 100 mg
together with the final dose of omeprazole.
Cohort 2 was a single-dose, double-blind, parallel group
investigation in 16 healthy elderly individuals between 65
and 80 years of age. Subjects were randomized 3:1 to re-
ceive danirixin 100 mg or placebo in the fasting state.
Safety
For each subject, adverse events and serious adverse
events were collected from the start of first dosing until
the final follow-up contact. Safety was monitored by the
measurement of ECGs, vital signs, clinical laboratory as-
sessments (clinical chemistry, hematology, and urinaly-
sis), and assessment of adverse events.
Determination of danirixin concentrations in whole blood
and pharmacokinetic assessment
Whole blood concentrations of danirixin free base were
determined using a validated analytical method based on
extraction from a dried blood spot [9], with a 3 mm disc
being punched from a 0.015 mL sample on Whatman
FTA™ cards. Danirixin was extracted using methanol
(0.1 mL) containing isotopically labeled [2H7]-danirixin
(racemic version of danirixin) at a concentration of
50 ng/mL as an internal standard. The extraction tubes
were shaken for 1 h at ambient temperature, prior to the
Fig. 2 Study design algorithm for Study 1 (FTIH)
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supernatant being transferred to clean tubes. The super-
natant (5 μL) was injected onto a high-performance liquid
chromatography system utilizing a Thermo Scientific
Hypersil Gold C18 (5 μm packing 50 × 4.6 mm) column
(supplied by Thermo Scientific, Hempstead, UK), eluted
using an isocratic composition: 55:45 (v/v) of aqueous
10 mM ammonium formate containing 0.1 % formic acid
(A) and acetonitrile (B). Danirixin free base has a retention
time of approximately 1 min and was detected using tan-
dem mass spectrometry on a Sciex 5000 (Applied Biosys-
tems, Warrington, UK) using Turbolon Spray in positive
polarity mode. Mass transitions monitored were 84 and 89
from precursor ions of 442 and 449 for danirixin and the
internal standard. The assay had a linear dynamic range of
5 – 1000 ng/mL and quantification was performed using
peak area ratios with 1/×2 weighted linear regression.
Assay quality control samples were 15 ng/mL (low),
200 ng/mL (medium) and 800 ng/mL (high). The average
within-run precision (%CV) was 9.9, 7.2 and 9.0 respect-
ively, for the low, mid and high quality controls for study
CX3112483 and 18.9, 5.9 and 5.2, respectively, for the low,
mid and high quality controls for study CX3113722.
Pharmacokinetic parameters were determined from the
blood concentration-time data for danirixin. The pharma-
cokinetic parameters were calculated based on actual sam-
pling times using standard non-compartmental analysis in
WinNonlin Professional, Version 5.2. The area under the
blood concentration-time curve (AUC) was determined
from the time of dosing to the last quantifiable concen-
tration (AUC(0-t)) using the lin – log trapezoidal rule. The
apparent terminal elimination half-life (t1/2) was obtained
as the ratio of ln2/λz, where λz is the terminal phase rate
constant, estimated by linear regression through the log
transformed terminal data. AUC(0-t) was extrapolated to
infinity (AUC(0-∞)) as the sum of AUC(0-t) and Ct/λz, where
Ct is the last observed blood concentration and λz is the
terminal phase rate constant.
Flow cytometric analysis of CD11b expression on blood
neutrophils
CXCR2 ligand-induced cell surface expression of CD11b
has been demonstrated to be a useful pharmacodynamic
biomarker for the effects of CXCR2 antagonists [4]. To
assess the pharmacodynamic effects of danirixin follow-
ing oral administration, CXCL1-induced CD11b cell sur-
face expression on blood neutrophils was determined
with a whole blood assay as previously described [4, 10].
Statistical analyses
Study 1
The primary endpoint was safety and tolerability assessed
by clinical monitoring of blood pressure, pulse rate, ECG,
and clinical laboratory assessments as well as reporting
of adverse events. Secondary endpoints included: 1) AUC
(0-∞), AUC (0-t), maximum blood concentration (Cmax),
time to maximum blood concentration (Tmax), and ter-
minal half-life (t1/2). 2) ex vivo CXCL1-induced CD11b cell
surface expression on peripheral blood neutrophils, and 3)
the relationship between the blood concentration of
Fig. 3 Study design algorithm for Study 2 (Fed versus Fasted, Elderly, Omeprazole Interaction)
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danirixin and ex vivo CXCL-1-induced CD11b cell sur-
face expression on peripheral blood neutrophils.
In the single dose cohorts, dose proportionality was
calculated on AUC (0 to ∞) and Cmax for Cohorts 1
and 2 and repeated again with Cohorts 1, 2, and 5. The
power model analysis was performed on loge-trans-
formed AUC (0 to ∞) and Cmax for danirixin. For each
of these parameters, a mixed effects model was fitted
with loge (dose) as a fixed effect and individual subject
intercept fitted as random effects. Estimates of the mean
slope of loge (dose) were reported along with corre-
sponding 90 % confidence intervals.
To evaluate the accumulation ratio and time invari-
ance of the repeat dose cohorts, a statistical analysis was
performed after a log transformation of the data from all
active treatment groups. A mixed effect model was fitted
with treatment group, day, and treatment group by day
interaction as fixed effects and subject as a random
effect. Day 14 was compared with Day 1 in order to esti-
mate the accumulation ratio and time invariance ratios
for each treatment group. The ratios were calculated by
back-transforming the difference between the least
squares means. Using the pooled estimate of variance,
90 % confidence intervals were calculated for the differ-
ence and then back-transformed.
A mixed effects model was used to analyze the ratio to
baseline fractional increase from control CD11b values
over time. The model included the same effect as men-
tioned above except for time (hours). Subject was fitted
as a random effect. In the repeat dose cohorts, a mixed
effects model was used to analyze the ratio to baseline
fractional increase from control CD11b values (treat-
ment group for all pre-treatment data was set to the
same dummy value, regardless of the treatment the sub-
ject went on to receive). The model included the follow-
ing fixed effects (effects were fitted as categorical: time
(hours) and treatment. Treatment*time and time* base-
line interactions were fitted. For each day, a separate
mixed model was fitted with time.
Another mixed effects model was used to analyze the
weighted mean (0–9 h) ratio to baseline fractional increase
from control CD11b values. The model included the
following fixed effects (effects were fitted as categorical):
day and treatment. Treatment*day interaction was fitted.
In the single and repeat dose cohorts, adjusted geometric
means for each treatment and time point were calculated
along with 95 % CIs. Point estimates of the treatment
differences (each danirixin dose vs. placebo) and their
associated 95 % confidence intervals were also calculated
(using the pooled estimate of variance) and were back-
transformed to provide point estimates and 95 % confi-
dence intervals for the ratios. The ratios were converted
into percent values to give the percent inhibition of danir-
ixin versus placebo and 95 % confidence intervals.
A Bayesian analysis was conducted to derive the pos-
terior probability distributions for the ratio to baseline
fractional increase from control CD11b values at 24 h.
The probabilities of seeing the percent inhibition of
danirixin versus placebo greater than 0 %, 50 % and
greater than 60 % were derived from the frequentist ana-
lysis mixed effects model. A students T cumulative dis-
tribution function was used to obtain the probabilistic
statements, assuming a non-informative prior.
Study 2
The pharmacokinetic parameters AUC (0 to 24 h), AUC
(0 to ∞), and Cmax were derived from the blood con-
centration of study drug. To assess age and gender, the
exposures from Cohorts 1 and 2 (both in the fasted
state) were combined. Following loge-transformation,
AUC (0 to ∞) and Cmax of study drug were separately
analyzed using a mixed effects model with fixed effect
terms age and gender. Age-gender interaction was fitted
and explored. To estimate the food effect on the primary
pharmacokinetic endpoint, data from Cohort 1 were
used. Following loge-transformation, AUC (0 to ∞) and
Cmax of study drug were separately analyzed using a
mixed effects model with fixed effect terms for regimen
and period. Subject was treated as a random effect in
the model. The same method of analysis, as for the food
effect analysis, was applied to estimate the repeat oral
doses of omeprazole on the primary pharmacokinetic
endpoints, except for the exclusion of period from the
model. In the single dose cohorts, a mixed effects model
was used to analyse the ratio to baseline fractional in-
crease from control CD11b values. The model included
the following fixed effects (effects were fitted as cate-
gorical): period (6 levels), time (hours) and treatment.
Subject baseline and period baseline were fitted as con-
tinuous covariates. Treatment*time and time*period




Thirty subjects were enrolled in the FTIH study and re-
ceived at least one dose of study drug. One subject
withdrew consent and withdrew from the study. Sixteen
subjects were enrolled in Cohort 1 of Study 2; one subject
was withdrawn after withdrawing consent. Sixteen subjects
enrolled in Cohort 2 of Study 2; all subjects completed the
study. The demographics and baseline characteristics for
these subjects are shown in Tables 1 and 2.
Safety and tolerability
There were no serious adverse events and no subjects
withdrawn due to adverse events. The most frequent
adverse event during the FTIH study, irrespective of
Miller et al. BMC Pharmacology and Toxicology  (2015) 16:18 Page 5 of 12
causality, was headache, which occurred in 14 subjects
(5 subjects on placebo, 1 subject each on 10 mg and
100 mg single dose, 2 subjects each on 200 mg and
400 mg single dose, and 2 subjects on 200 mg repeat
dose). Headache that was considered by the investigator
to be possibly related to drug treatment occurred in 9
subjects (12 %). Somnolence occurred in five subjects
(1 subject on placebo, 1 subject each on 10 mg and
200 mg single dose, and 2 subjects on 100 mg). Hot
flushes occurred in four subjects (2 subjects on placebo,
1 subject on 200 mg single dose, and 1 subject on
200 mg repeat dose). Abdominal pain occurred in 4 sub-
jects (1 subject each on 10 mg and 200 mg single dose and
1 subject each receiving 50 mg and 200 mg repeat dose).
In Study 2, 11 subjects reported 12 adverse events
(34 %). Four adverse events were reported in subjects
receiving danirixin 100 mg in the fasted state (headache,
dizziness, nausea, and infusion site hemorrhage). Two
adverse events were reported in subjects receiving danir-
ixin 100 mg in the fed state (headache, dyspepsia). Two
adverse events were reported in combination with
omeprazole (nasopharyngitis, sinusitis). Three adverse
events were reported in elderly subjects receiving danir-
ixin 100 mg in the fasted state (application site rash,
back pain, and dermatitis atopic) and one adverse event
was reported in subjects receiving placebo (viral gastro-
enteritis). There were no reports of neutropenia or sus-
tained decreases in neutrophil count. However, in the
FTIH study, one subject was withdrawn from the study
after the reduction in neutrophil levels met protocol
stopping criteria of less than 1.5 × 109/L; the neutrophil
count was fully reversed upon discontinuation of study
drug. This subject was noted to have a low normal neu-
trophil count at screening (1.9 × 109/L).
Study 1: FTIH
Cohorts 1, 2, and 5 (single dose)
Systemic exposure to single daily doses of danirixin
10 mg, 25 mg, 50 mg, 100 mg (as 2 × 50 mg tablets),
and 200 mg increased with increasing dose. The slope
log versus log for the (AUC) (0 to ∞ was 1.122 (90 % CI:
0.992, 1.253) and for Cmax was 1.046 (90 % CI: 0.919,
1.172) indicating a proportional increase across the dose
range. However, the 100 mg dose (2 × 50 mg) deviated
from the dose proportionality shown by the other dose
levels and had similar exposure results to 50 mg. The
addition of danirixin 400 mg (Cohort 5) in the power
model suggested a dose proportional increase in Cmax
over the 10–400 mg dose range (1.019; 90 % CI: 0.913,
1.126) but a deviation away from dose proportionality
for AUC(0-∞) (1.117; 90 % CI: 1.001, 1.234).
The time at which the maximum blood concentrations
were observed (Tmax) was consistent across the dose
range studied (median: 1–2 h; range: 1 to 3 h). The ap-
parent terminal half-life was approximately 6 h and was
consistent across the dose range studied.
Figure 4 shows the individual and geometric means
of danirixin blood dose-normalized Cmax versus dose
using 10 mg as a reference dose. Subjects dosed with
100 mg had a lower Cmax than predicted and four sub-
jects had higher Cmax values than expected (two subjects
Table 1 Demographics and baseline characteristics of study subjects, Study 1 (FTIH)
Cohorts 1
and 2
Cohorts 3 and 4 Cohort 5
Placebo RD danirixin 50 mg RD danirixin 200 mg RD Placebo SD danirixin 400 mg SD
Age, yrs mean (SD) 35 (13) 35 (8) 29 (10) 33 (14) 27 (5) 25 (4)
n, (% male) 30 (100 %) 8 (100 %) 10 (100 %) 10 (100 %) 5 (100 %) 10 (100 %)
Race, n (%)
White 25 (83) 6 (75) 10 (100) 9 (90) 4 (80) 7 (70)
African-American 3 (10) 2 (25) 0 0 1 (20) 1 (10)
Asian 2 (6) 0 0 1(10) 0 2 (20)
BMI (kg/m2) mean (SD) 25 (2) 26 (3) 25 (2) 25 (3) 24 (4) 24 (2)
Table 2 Demographics and baseline characteristics of study
subjects, study 2 (fed vs. fasted, elderly, omeprazole interaction)
Study 2, Fed vs. Fasted Mean (range)
Part A Part B
danirixin Placebo
Age, years, mean (SD) 51 (8) 70 (2) 70 (6)
Sex (M/F) 8/8 6/6 2/2
Ethnicity, n (%)
Hispanic/Latino 6 (38) 0 0
Not Hispanic/Latino 10 (63) 12 (100) 4 (100)
Race, n (%)
African-American 1 (6) 0 0
White 15 (94) 11 (92) 4 (100)
Mixed 0 1 (8) 0
Height (cm), mean (SD) 174 (7) 172 (11) 171 (8)
Weight (kg), mean (SD) 80 (11) 80 (13) 77 (15)
BMI (kg/m2), mean (SD) 26 (3) 27 (3) 26 (3)
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Fig. 4 Plot of individual subject danirixin blood dose-normalized AUC (A) and Cmax (B) versus dose for cohorts 1, 2, and 5 in Study 1 (FTIH). The
geometric means (with 90 % confidence intervals) are also shown
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randomized to 10 mg followed by 200 mg and two sub-
jects randomized to 50 mg followed by 200 mg). These
four subjects also had a comparatively high AUC(0-∞). One
subject had a high AUC(0-∞) following dosing with danir-
ixin 50 mg but over 2-fold lower AUC(0-∞) than expected
following dosing with danirixin 200 mg. Following dosing
with danirixin 400 mg, two subjects had higher Cmax than
expected and also had higher AUC(0-∞).
Cohorts 3 and 4 (14-day repeat dose)
Repeat dosing of danirixin 50 mg and 200 mg resulted
in lower exposure on Day 14 than on Day 1. The ratio of
adjusted geometric means for AUC (0-t) was 0.846 (90 %
CI: 0.553, 1.295) for danirixin 50 mg and 0.989 (90 % CI:
0.619, 1.579) for danirixin 200 mg after repeat dosing.
An analysis of AUC and terminal half-life was performed
to assess time invariance following repeat dosing with
danirixin 50 mg and 200 mg. The AUC exposures were
less, on average, on Day 14 compared with Day 1. An
average decrease of 21 % (90 % CI: −48 %, 20 %) and
7 % (90 % CI: −42 %, 47 %) was observed for danirixin
50 mg and 200 mg, respectively, indicating that there
was no evidence of time invariance. The t½ was greater
on average by 33 % (90 % CI:-3 %, 82 %) on Day 14 com-
pared with Day 1 for danirixin 50 mg, suggesting no evi-
dence of time invariance based on t½. However, there
was evidence to suggest an increase in t½ on Day 14
compared with Day 1 for danirixin 200 mg as t½, on
average, was greater by 71 % (90 % CI: 26 %, 131 %).
CD11b surface expression on neutrophils
Approximately 50 % inhibition in weighted mean (0–9 h)
CXCL1-induced CD11b expression was observed follow-
ing single doses of danirixin 50 mg (ratio of active to
placebo 0.445; 95 % CI: 0.257, 0.772) and 100 mg (0.502;
95 % CI: 0.299, 0.845) and 72 % inhibition (0.282; 95 %
CI: 0.161, 0.493) following 200 mg compared with pla-
cebo. The ratio to baseline fractional increase from
control CD11b expression at 24 h for single doses of
danirixin 50 mg, 100 mg (2 × 50 mg), and 200 mg was
1.908 (95 % CI: 0.853, 4.265), 1.326 (95 % CI: 0.565, 3.110),
and 0.516 (95 % CI: 0.212, 1.255), respectively. Bayesian
Fig. 5 Adjusted geometric means of ratio to baseline ex vivo CXCL-induced CD11b expression (0–24 h) versus time for single dose Study 1 (FTIH):
fractional increase from control (CXCL1 0 nM) with 95 % CIs
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analyses revealed that the probability of danirixin inhibit-
ing CXCL1-induced CD11b expression relative to placebo
at 24 h postdose at single doses of 50 mg, 100 mg, and
200 mg was 0.057, 0.26, and 0.93, respectively.
Repeat doses of danirixin 50 mg demonstrated an aver-
age of 67 % and 70 % weighted mean (0 to 9 h) CXCL1-
induced CD11b inhibition on day 1 (0.335; 95 % CI: 0.227,
0.495) and day 14 (0.399; 95 % CI: 0.258, 0.617), respect-
ively, relative to placebo. Repeat doses of danirixin 200 mg
demonstrated an average of 70 % and 50 % weighted mean
(0 to 9 h) CXCL1-induced CD11b inhibition on day 1
(0.301; 95 % CI: 0.209, 0.435) and day 14 (0.501; 95 % CI:
0.319, 0.788), respectively, relative to placebo. Bayesian
analyses revealed that the probability of repeat doses of
danirixin 200 mg inhibiting CXCL1-induced CD11b ex-
pression relative to placebo was 1.0.
In general, repeat doses of danirixin 50 mg and
200 mg demonstrated an average of 50 % inhibition in
CXCL1-induced CD11b expression at various time
points over the 24 h post dose on Day 1 (Fig. 5) and for
most time points on Day 14, though high variability was
observed across all treatments. The ratio to baseline
fractional increase from control CD11b expression at
24 h for repeat doses of danirixin 50 mg on Day 1 was
0.374 (95 % CI: 0.132, 1.057) and on Day 14 was 0.403
(95 % CI: 0.226, 0.718). The ratio to baseline fractional
increase from control CD11b expression at 24 h for re-
peat doses of danirixin 200 mg on Day 1 was 0.303
(95 % CI: 0.107, 0.861) and Day 14 was 0.348 (95 % CI:
0.192, 0.631). Fig. 6 shows the concentration-response
plot for the effect of danirixin on the CXCL1-induced
CD11b expression (shown in terms of percent inhib-
ition), and clearly shows that a direct relationship exists
between blood concentrations of danirixin and reduction
in CXCL1-induced CD11b expression. Population PK/
PD modeling of the data from the FTIH study suggests
that the maximum possible inhibition of CXCL1-
induced CD11b expression could be achieved and that
the IC50 for this inhibition was 69 ng/mL (95 % CI: 17.6
to 120 ng/mL).
Study 2: Fed/fasted, omeprazole interaction and elderly
pharmacokinetics
There was a statistically significant reduction in Cmax of
37 % (90 % CI: 24 % to 48 %) when danirixin 100 mg
was administered following food (Table 3 and Fig. 7).
The average decrease of 16 % in AUC(0-∞) following ad-
ministration in the presence of food was not statistically
significant (90 % CI: −3.1 % to 32 %). The median Tmax
was delayed in the presence of food compared with that
in fasted subjects (3 h and 2 h, respectively). There was
some evidence of a period effect, with lower average
Cmax and less variability in Cmax in Period 2. There
was also some evidence of a treatment-period inter-
action. Subjects randomized to fasted followed by fed
had lower average Cmax and AUC(0-∞) in the fed period,
Fig. 6 Plot of inhibition of ex vivo CXCL1-induced CD11b expression versus whole blood concentration of danirixin for Study 1. The plot shows
all timepoints where results are available for both danirixin whole blood concentration and ex vivo CXCL1-induced CD11b expression
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while subjects on the other treatment sequence had
higher average Cmax and AUC(0-∞) in the fed period.
Subjects with the highest exposure in the danirixin
100 mg fasted period did not also have the highest
exposure in the danirixin 100 mg fed period.
There was a reduction in exposure when danirixin was
administered following dosing with omeprazole 40 mg once
daily for 5 days (Fig. 5). The decreases of 56 % for AUC(0-∞)
(90 % CI: 41 % to 66 %) and 64 % for Cmax (90 % CI: 50 %
to 73 %) were statistically significant, while the median
Tmax was unchanged at 2 h for both treatments (Table 4).
In elderly subjects receiving danirixin 100 mg, the
AUC(0-∞) and Cmax were approximately half that ob-
served for subjects aged 40 to 64 years (AUC[0-∞], 90 %
CI: 14 % to 73 %; Cmax, 90 % CI: −2.5 % to 73 %). In
addition, the median Tmax for the fasted elderly cohort
was earlier than that of the younger fasted cohort (1.5 h
compared to 2 h).
Female subjects had approximately 1.5-fold higher
average exposures compared to males (AUC[0-∞], 90 %
CI: 0.826 to 2.604; Cmax, 90 % CI: 0.806 to 3.064). How-
ever, due to the wide variability, these apparent differ-
ences between the sexes were not statistically significant.
An exploratory analysis suggested that the absorption of
danirixin was higher and that the clearance was lower in
female subjects compared to male subjects. There was
no evidence of an age-gender interaction; however, as
the data are highly variable and the populations were
Table 3 Summary of statistical analysis of fed/fasted comparison (Study 2)
Danirixin 100 mg Fed Danirixin 100 mg Fasted Treatment Difference(Fed vs. Fasted)
n Adjusted Geometric Mean(SE Logs) n Adjusted Geometric Mean(SE Logs) Estimate 90 % CI
AUC (0-∞)(ng h/mL) 15 12,635 (0.082) 13 15,047 (0.088) 0.840 (0.684, 1.031)
Cmax(ng/mL) 16 1411 (0.076) 15 2239 (0.078) 0.630 (0.523, 0.758)
Fig. 7 Mean pharmacokinetics concentration plot versus time for Study 2 (Fed versus Fasted, Elderly, Omeprazole Interaction)
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imbalanced in terms of male and female age ranges, fur-
ther work is needed to adequately define the importance
of age and gender on the absorption of danirixin.
Discussion
The data presented in this report are from the first two
clinical studies with danirixin in humans to assess the
initial safety, tolerability, pharmacokinetics and pharma-
codynamics of single and repeated doses under conditions
relevant to the target patient population. Administration
of danirixin was generally well-tolerated at single doses up
to 400 mg and following once daily dosing for 14 days at
doses of 50 mg and 200 mg. Importantly, subjects did not
develop low neutrophil counts or overt neutropenia, as
has been reported with other CXCR2 antagonists [6–8].
Danirixin demonstrated a dose-dependent inhibition of
CXCL1-induced CD11b expression following single doses
between 50 to 200 mg, which was maintained after 14 days
of dosing. The optimal extent of pharmacodynamic activ-
ity needed is unknown, but it is likely that less than
complete inhibition of CXCR2 activity is desirable in
order to obtain a balance between clinical benefit, while
minimizing the impact on innate immunity and host
defense. Although the magnitude and duration of
CXCR2 antagonism needed to achieve a pharmacologic
and clinical effect in disease are unknown the pharma-
cokinetic data suggest that twice-daily dosing with
danirixin may be needed to maintain blood concentra-
tions at an appropriate level.
The prevalence of gastroesophageal reflux disease
(GERD) and the use of gastric acid suppressing agents in
COPD, one of the disease targets for a CXCR antagonist,
is high [11–13]. Proton pump inhibitors have been re-
ported to increase intragastric pH above 4.0 for approxi-
mately 50 % of the time over a 24 h interval [14]. Acidic
conditions are required for optimal dissolution of danir-
ixin. The formulation strategy for danirixin has thus
far been focused on optimizing the disintegration and
dissolution of the product in the stomach, which would
then be expected to deliver a solution of the drug for ab-
sorption to the duodenal region of the small intestine. An
intra-gastric pH at a steady state above 4.0 during a sig-
nificant proportion of the day has potential implications
for the solubility and absorption of danirixin. Statistically
significant reductions in danirixin AUC and Cmax were
observed in the presence of omeprazole.
The effect of omeprazole on the bioavailability of
danirixin suggests an important drug interaction re-
quiring further evaluation to determine appropriate
dosing recommendations in patients using gastric acid
reducing agents. Additional drug interactions that
may impact danirixin have not been evaluated. How-
ever, one study has assessed the potential for meta-
bolic drug interactions. In this study a bile sample
was obtained using a non-invasive sampling technique
[15]. The results demonstrated that glucuronide con-
jugation is likely to be the major route of metabolism
for danirixin. Oxidative metabolism contributed only
in a minor way indicating that cytochrome P450-
mediated drug interactions are not likely to be a con-
cern for danirixin.
In the presence of a high fat meal, the AUC and Cmax
data suggest that the rate, but not the extent of absorp-
tion of danirixin was reduced, as would be expected
from a molecule with this solubility profile. Furthermore,
these data also suggest that in the fasted state the aver-
age exposure to danirixin in the elderly was half that of
younger subjects, as reflected by lower AUC and Cmax
measurements. In addition, in the fasted state, very high
inter-subject variability in the exposure measurement
was observed in elderly subjects. Administration of
danirixin with food resulted in reduced variability in a
range that is considered acceptable.
Conclusions
The data in the reported studies indicate that danirixin
was well-tolerated, with a favorable pharmacokinetic
and pharmacodynamic profile in healthy adult sub-
jects, including elderly subjects. The dose-dependent
inhibition of CXCL1-induced CD11b expression fol-
lowing single doses between 50 to 200 mg suggests the
potential for clinical benefit in disease indications
where an excessive neutrophil response has an important
role in pathogenesis. The co-administration of daily omep-
razole and use in the elderly will have to be taken into
consideration when progressing to evaluation in patient
populations.
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